- Home
- TCBI vs MIRM Comparison
TCBI vs MIRM Comparison
Compare TCBI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBI
- MIRM
- Stock Information
- Founded
- TCBI 1996
- MIRM 2018
- Country
- TCBI United States
- MIRM United States
- Employees
- TCBI N/A
- MIRM N/A
- Industry
- TCBI Major Banks
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- TCBI Finance
- MIRM Health Care
- Exchange
- TCBI Nasdaq
- MIRM Nasdaq
- Market Cap
- TCBI 2.9B
- MIRM 2.5B
- IPO Year
- TCBI N/A
- MIRM 2019
- Fundamental
- Price
- TCBI $85.85
- MIRM $50.30
- Analyst Decision
- TCBI Hold
- MIRM Strong Buy
- Analyst Count
- TCBI 15
- MIRM 9
- Target Price
- TCBI $77.47
- MIRM $66.22
- AVG Volume (30 Days)
- TCBI 445.1K
- MIRM 468.1K
- Earning Date
- TCBI 07-17-2025
- MIRM 08-06-2025
- Dividend Yield
- TCBI N/A
- MIRM N/A
- EPS Growth
- TCBI N/A
- MIRM N/A
- EPS
- TCBI 1.74
- MIRM N/A
- Revenue
- TCBI $891,496,000.00
- MIRM $379,251,000.00
- Revenue This Year
- TCBI $44.91
- MIRM $35.83
- Revenue Next Year
- TCBI $9.57
- MIRM $16.83
- P/E Ratio
- TCBI $49.46
- MIRM N/A
- Revenue Growth
- TCBI N/A
- MIRM 69.31
- 52 Week Low
- TCBI $56.24
- MIRM $33.52
- 52 Week High
- TCBI $91.80
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- TCBI 79.17
- MIRM 59.09
- Support Level
- TCBI $76.81
- MIRM $47.89
- Resistance Level
- TCBI $84.13
- MIRM $51.93
- Average True Range (ATR)
- TCBI 3.04
- MIRM 1.49
- MACD
- TCBI 0.81
- MIRM -0.25
- Stochastic Oscillator
- TCBI 96.38
- MIRM 59.65
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.